Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Cardarine (GW-501516) | S-23 | |
|---|---|---|
| Category | SARMs | SARMs |
| Standard Dose | Research indicates 10-20 mg daily orally for 8-12 weeks. Clinical trials (metabolic syndrome) used 2.5-10 mg/day. | Research indicates 10-25 mg daily orally for 8-12 weeks. No human clinical trials — dosing extrapolated from rat pharmacology and anecdotal reports. |
| Timing | Once daily, 1-2 hours before exercise for acute endurance benefit. Half-life approximately 16-24 hours. Consistent daily dosing. | Split into 2 daily doses due to relatively short half-life (~12 hours). Morning and evening dosing. |
| Cycle Duration | 8-12 week cycles. No HPG suppression, so PCT is not required. However, long-term safety is unknown and cycling is prudent. | 8 week cycles maximum recommended. PCT is absolutely mandatory due to profound HPG suppression. Allow full recovery before considering subsequent cycles. |
| Evidence Level | animal_plus_anecdotal | animal_plus_anecdotal |
Cardarine is a selective peroxisome proliferator-activated receptor delta (PPARd) agonist, not a SARM (it does not bind the androgen receptor). PPARd activation in skeletal muscle upregulates genes for fatty acid oxidation (CPT1B, PDK4, ACOX1), shifting fuel substrate from glycolysis toward beta-oxidation, effectively increasing endurance capacity and fat utilization. It increases oxidative type I (slow-twitch) muscle fiber proportion, enhances mitochondrial biogenesis via PGC-1a coactivation, reduces circulating triglycerides and LDL, and increases HDL cholesterol. PPARd activation also reduces macrophage-mediated inflammation through NF-kB suppression.
Research indicates 10-20 mg daily orally for 8-12 weeks. Clinical trials (metabolic syndrome) used 2.5-10 mg/day.
Once daily, 1-2 hours before exercise for acute endurance benefit. Half-life approximately 16-24 hours. Consistent daily dosing.
8-12 week cycles. No HPG suppression, so PCT is not required. However, long-term safety is unknown and cycling is prudent.
S-23 is one of the most potent nonsteroidal SARMs developed, originally investigated by GTx, Inc. as a potential male hormonal contraceptive. It binds the androgen receptor with very high affinity, producing near-steroidal anabolic effects in muscle and bone while profoundly suppressing FSH and LH, leading to oligospermia and azoospermia in animal models. S-23 increases lean body mass and bone mineral density while reducing fat mass in a dose-dependent manner. The contraceptive effect was fully reversible in rat studies — spermatogenesis and fertility recovered completely after a 100-day washout period.
Research indicates 10-25 mg daily orally for 8-12 weeks. No human clinical trials — dosing extrapolated from rat pharmacology and anecdotal reports.
Split into 2 daily doses due to relatively short half-life (~12 hours). Morning and evening dosing.
8 week cycles maximum recommended. PCT is absolutely mandatory due to profound HPG suppression. Allow full recovery before considering subsequent cycles.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →